


FIGURE 1A



SDS


CHAPS

Igepal

Urea

DTT


FIGURE 1B



SDS

FIGURE 2A

Patient 1: cTnl



Patient 1: cTnT




FIGURE 2B
Patient 2: cTnl




FIGURE 2C
Patient 3: cTnl




FIGURE 2D
Patient 4: cTnl





FIGURE 2E
Patient 5: cTnl






FIGURE 3




FIGURE 4





FIGURE 5

Appearance of Troponin I Degradation Products in Serum of Patients given Anti-Thrombolytic Therapy Demonstrates that cTnI is Modified in the Myocardium Prior to Release into the Circulation




H refers to samples that were hemolyzed

FIGURE 6

Respiratory patient

FIGURE 7A

mAb : F-32



Rhabdomyolysis patient

FIGURE 7B

mAb : F-32




FIGURE 7C

mAb : 3I-35





FIGURE 7D

mAb : 3I-35



Respiratory patient

FIGURE 8A

Fast skeletal TnI mAb





FIGURE 8C

Slow skeletal TnI mAb



Rhabdomyolysis patient

FIGURE 8B

Fast skeletal TnI mAb





FIGURE 8D

Slow skeletal TnI mAb



Rhabdomyolysis patient

FIGURE 9A
Fast skeletal TnI




FIGURE 9B
Prolonged exposure




FIGURE 9C
Slow skeletal TnI

